innoModels Secures ￥10M in the First Round of Financing

(VCBeat) Feb. 9, 2021 -- At the beginning of 2021, Chuangmo Biotechnology (Beijing) Co., Ltd. ("innoModels") today announced it has closed RMB 10 million in its first financing round with participation from Dalton Venture and Sunforest Capital, with the financing agreement signed and completed at the end of 2020. 

Founded in 2016 and formerly known as Beijing Feinuoke Biotechnology, innoModels is a CRO company that focuses on oncology and immune-oncology pharmacodynamics. Since its establishment, the company is committed to the R&D of in vitro and experimental animal models for the next generation of immune-oncology pharmacodynamics.

Through the innovation of mouse models, high-quality products, and strict processes, innoModels provides the pharmacodynamics data closest to the clinical efficacy for well-known pharmaceutical companies, biotech companies, and research institutes at home and abroad.

In October 2020, innoModels completed the equity restructuring and officially changed its name to Chuangmo Biotechnology (Beijing) Co., Ltd., and successfully established its subsidiary Chuangmo Pharmaceutical Technology (Beijing) Co., Ltd. 

Based on the new generation of NIG severe combined immunodeficiency mice with independent intellectual property rights, innoModels has developed a variety of Humanized drug testing platforms, as well as the humanized immune system-PDX platforms, to meet the demands of new drug developers. 

The core team of innoModels comes from well-known pharmaceutical enterprises in China and the United States, with many years of experience in the development of model animals. The company has branches in Beijing, Shanghai, and Shenzhen. 

Dalton Venture is focused on early-stage investment and mergers and acquisitions in the healthcare industry, with a focus on medical services and innovative medical technologies. The core team of Dalton Venture is from the medical and healthcare industry, with rich experience in enterprise operation management, investment, and mergers & acquisitions.

Founded in 2016, Sunforest Capital focuses on investments in the world's top biomedical technology. The company aims to build a first-class medical and health investment and financing platform. Sunforest Capital provides services in four sectors: angel investments, co-entrepreneurship, financial consultant and special funds.